Last reviewed · How we verify
NCT04034901: DACRE
Study of Physiological Signals During and After COPD Exacerbations
NA trial testing Monitoring of cardiorespiratory parameters with BORA Band in COPD in 42 participants. Completed in 6 February 2024.
6 February 2024
Quick facts
| Lead sponsor | Biosency |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 42 |
| Start date | 19 February 2021 |
| Primary completion | 6 February 2024 |
| Estimated completion | 6 February 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Monitoring of cardiorespiratory parameters with BORA Band
Conditions studied
- COPD — all drugs for COPD →
- COPD Exacerbation — all drugs for COPD Exacerbation →
Sponsor
Biosency
Who can join
18 and older, any sex, with COPD or COPD Exacerbation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background : Acute exacerbations of COPD (Chronic Obstructive Pulmonary Disease) are frequent events in the course of the disease and they can deteriorate the respiratory function of the patients, impact their quality of life and even potentially threaten their life. It is therefore crucial to prevent these exacerbations from occurring. Aim of the study : Investigate how cardiorespiratory parameters of COPD patients differ between exacerbation phases and their nominal state in order to identify predictors of COPD exacerbations. Study design : Patients admitted at one of the investigation centers on a suspicion of COPD exacerbation will be enrolled on a voluntary basis. Enrolled patients' cardiorespiratory parameters will be monitored with a connected wrist-worn pulse oximeter (BORA Band) during the hospitalisation phase and one month after they have been discharged. Setting : 4 investigative centers across Brittany Patients : 50 patients will be enrolled in the study
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Validity of Ultra-Short-Term HRV Analysis Using PPG-A Preliminary Study.
Taoum A, Bisiaux A, Tilquin F, Le Guillou Y, et al · · 2022 · cited 13× · PMID 36298346 · DOI 10.3390/s22207995
Verify or expand the search:
- PubMed search for NCT04034901
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COPD
Currently open trials in the same condition.
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
- NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
Other Biosency trials
Trials by the same sponsor.
- NCT04064645 — Bora Band Respiration Rate Study · NA · completed
- NCT03918018 — BiOSENCY BORA Band SpO2 Validation Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04034901 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biosency
- Last refreshed: 15 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04034901.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing